Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients

被引：21

作者：

Koval, Christine E. ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Dept Infect Dis, 9500 Euclid Ave,Box G21, Cleveland, OH 44195 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 03期

关键词：

CMV; Cytomegalovirus; Herpesvirus infection; Solid organ transplantation; CMV prophylaxis; CMV treatment; EXTENDED VALGANCICLOVIR PROPHYLAXIS; ANTICYTOMEGALOVIRUS COMPOUND AIC246; HEMATOPOIETIC-CELL TRANSPLANTATION; DRUG-RESISTANT CYTOMEGALOVIRUS; SINGLE-CENTER; STEM-CELL; GANCICLOVIR-RESISTANT; LUNG TRANSPLANTATION; MEDIATED-IMMUNITY; CLINICAL-ASPECTS;

D O I：

10.1016/j.idc.2018.04.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Despite advances in prevention and treatment, cytomegalovirus (CMV) infection and disease remain an expected problem in solid organ transplant recipients. Because of the effect of immunosuppressing medications, CMV primary, secondary, and reactivated infection requires antiviral medications to prevent serious direct and indirect effects of the virus. Side effects and drug resistance, however, often limit the capacity of traditional antiviral therapies. This article updates the clinician on current and promising approaches to the management and control of CMV in the solid organ transplant recipient.

引用

页码：581 / +

页数：18

共 66 条

[1] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].

Asberg, A. ;

Humar, A. ;

Rollag, H. ;

Jardine, A. G. ;

Mouas, H. ;

Pescovitz, M. D. ;

Sgarabotto, D. ;

Tuncer, M. ;

Noronha, I. L. ;

Hartmann, A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113

[2]

Asberg A, 2006, AM J TRANSPLANT, V2009, P1205

[3] Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection [J].

Avery, Robin K. ;

Arav-Boger, Ravit ;

Marr, Kieren A. ;

Kraus, Edward ;

Shoham, Shmuel ;

Lees, Laura ;

Trollinger, Brandon ;

Shah, Pali ;

Ambinder, Rich ;

Neofytos, Dionysios ;

Ostrander, Darin ;

Forman, Michael ;

Valsamakis, Alexandra .

TRANSPLANTATION, 2016, 100 (10) :E74-E80

[4] LUNGS ARE A MAJOR ORGAN SITE OF CYTOMEGALOVIRUS LATENCY AND RECURRENCE [J].

BALTHESEN, M ;

MESSERLE, M ;

REDDEHASE, MJ .

JOURNAL OF VIROLOGY, 1993, 67 (09) :5360-5366

[5] Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation [J].

Battiwalla, M. ;

Paplham, P. ;

Almyroudis, N. G. ;

McCarthy, A. ;

Abdelhalim, A. ;

Elefante, A. ;

Smith, P. ;

Becker, J. ;

McCarthy, P. L. ;

Segal, B. H. .

TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (01) :28-32

[6]

BEERSMA MFC, 1993, J IMMUNOL, V151, P4455

[7] Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients [J].

Bodro, Marta ;

Sabe, Nuria ;

Llado, Laura ;

Baliellas, Carme ;

Niubo, Jordi ;

Castellote, Jose ;

Fabregat, Joan ;

Rafecas, Antoni ;

Carratala, Jordi .

LIVER TRANSPLANTATION, 2012, 18 (09) :1093-1099

[8] CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis [J].

Bonaros, Nikolaos ;

Mayer, Bernd ;

Schachner, Thomas ;

Laufer, Guenther ;

Kocher, Alfred .

CLINICAL TRANSPLANTATION, 2008, 22 (01) :89-97

[9] Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients [J].

Bonatti, Hugo ;

Sifri, Costi D. ;

Larcher, Clara ;

Schneeberger, Stefan ;

Kotton, Camille ;

Geltner, Christian .

SURGICAL INFECTIONS, 2017, 18 (02) :128-136

[10]

Brennan D C, 2011, Am J Transplant, V11, P2453, DOI 10.1111/j.1600-6143.2011.03674.x

← 1 2 3 4 5 6 7 →